A Multi-center, Single-arm, Open-label, Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 50 mg Subcutaneous Weekly Injection When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Period of LG-ECCL002 Study.

Trial Profile

A Multi-center, Single-arm, Open-label, Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 50 mg Subcutaneous Weekly Injection When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Period of LG-ECCL002 Study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 21 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 28 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top